Amgen also tested MariTide in a population with Type 2 diabetes, a group that tends to lose less weight with the new obesity ...

Increases of 2.5-fold were seen for women, 2.4-fold for Asians and Pacific Islanders, and 2.5-fold in the Midwest.

Shares of biotech company Amgen slid Tuesday morning, trading around 12% lower. The drop was significant enough to drag the entire Dow Jones Industrial Average lower, because the index is ...

Shares of Amgen (AMGN) are down $11.49, or 4%, to $282.51 in pre-market trading after the company reported data at 52 weeks in a Phase 2 study ...

The Biden administration is proposing a major expansion of how Medicare and Medicaid cover Wegovy and Zepbound ...

Amgen’s MariTide results are at the lower end of investors’ expectation of 20% to 25% weight loss. The much-anticipated ...

Stocks are shrugging off a new Trump tariff threat as the President-elect vows sweeping levies on the biggest U.S. trading ...

Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

CNBC’s Jim Cramer explains why he is keeping an eye on shares of Amgen.

--On pace for largest percent decrease since Oct. 27, 2000, when it fell 13.41% --Currently down two consecutive days; down 10.49% over this period --Worst two day stretch since the two days ending ...

The stock decline is on track to be Amgen's (AMGN) worst one-day percentage fall since a 13.4% drop on Oct. 27, 2000, according to Dow Jones Market Data. MariTide has the advantage over rival ...

Amgen Inc. shares fell after its experimental obesity shot helped patients lose up to 20% of their body weight in a yearlong ...